Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1987 1
1990 3
1991 4
1992 1
1993 1
1994 2
1995 2
1997 2
1999 1
2000 1
2002 1
2006 1
2008 1
2009 1
2010 5
2011 5
2012 8
2013 5
2014 5
2015 6
2016 9
2017 4
2018 5
2019 2
2020 3
2021 4
2022 2
2023 3
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

75 results

Results by year

Filters applied: . Clear all
Page 1
Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial.
Østergaard M, van Vollenhoven RF, Rudin A, Hetland ML, Heiberg MS, Nordström DC, Nurmohamed MT, Gudbjornsson B, Ørnbjerg LM, Bøyesen P, Lend K, Hørslev-Petersen K, Uhlig T, Sokka T, Grondal G, Krabbe S, Lindqvist J, Gjertsson I, Glinatsi D, Kapetanovic MC, Aga AB, Faustini F, Parmanne P, Lorenzen T, Giovanni C, Back J, Hendricks O, Vedder D, Rannio T, Grenholm E, Ljoså MK, Brodin E, Lindegaard H, Söderbergh A, Rizk M, Kastbom A, Larsson P, Uhrenholt L, Just SA, Stevens DJ, Bay Laurbjerg T, Bakland G, Olsen IC, Haavardsholm EA, Lampa J; NORD-STAR study group. Østergaard M, et al. Ann Rheum Dis. 2023 Oct;82(10):1286-1295. doi: 10.1136/ard-2023-224116. Epub 2023 Jul 9. Ann Rheum Dis. 2023. PMID: 37423647 Free article. Clinical Trial.
Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial.
Hetland ML, Haavardsholm EA, Rudin A, Nordström D, Nurmohamed M, Gudbjornsson B, Lampa J, Hørslev-Petersen K, Uhlig T, Grondal G, Østergaard M, Heiberg MS, Twisk J, Lend K, Krabbe S, Hyldstrup LH, Lindqvist J, Hultgård Ekwall AK, Grøn KL, Kapetanovic M, Faustini F, Tuompo R, Lorenzen T, Cagnotto G, Baecklund E, Hendricks O, Vedder D, Sokka-Isler T, Husmark T, Ljoså MA, Brodin E, Ellingsen T, Söderbergh A, Rizk M, Olsson ÅR, Larsson P, Uhrenholt L, Just SA, Stevens DJ, Laurberg TB, Bakland G, Olsen IC, van Vollenhoven R; NORD-STAR study group. Hetland ML, et al. BMJ. 2020 Dec 2;371:m4328. doi: 10.1136/bmj.m4328. BMJ. 2020. PMID: 33268527 Free PMC article. Clinical Trial.
Risk of flare after tapering or withdrawal of biologic/targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or axial spondyloarthritis: a systematic review and meta-analysis.
Uhrenholt L, Christensen R, Dinesen WKH, Liboriussen CH, Andersen SS, Dreyer L, Schlemmer A, Hauge EM, Skrubbeltrang C, Taylor PC, Kristensen S. Uhrenholt L, et al. Among authors: schlemmer a. Rheumatology (Oxford). 2022 Aug 3;61(8):3107-3122. doi: 10.1093/rheumatology/keab902. Rheumatology (Oxford). 2022. PMID: 34864896
Disease activity-guided tapering of biologics in patients with inflammatory arthritis: a pragmatic, randomized, open-label, equivalence trial.
Uhrenholt L, Christensen R, Dreyer L, Hauge EM, Schlemmer A, Loft AG, Rasch M, Horn HC, Gade KH, Østgård RD, Taylor PC, Duch K, Kristensen S. Uhrenholt L, et al. Among authors: schlemmer a. Scand J Rheumatol. 2023 Sep;52(5):481-492. doi: 10.1080/03009742.2023.2164979. Epub 2023 Feb 6. Scand J Rheumatol. 2023. PMID: 36745114 Clinical Trial.
Auditing chronic disease care: Does it make a difference?
Essel V, van Vuuren U, De Sa A, Govender S, Murie K, Schlemmer A, Gunst C, Namane M, Boulle A, de Vries E. Essel V, et al. Among authors: schlemmer a. Afr J Prim Health Care Fam Med. 2015 Jun 26;7(1):753. doi: 10.4102/phcfm.v7i1.753. Afr J Prim Health Care Fam Med. 2015. PMID: 26245615 Free PMC article.
A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial.
Axelsen MB, Eshed I, Hørslev-Petersen K, Stengaard-Pedersen K, Hetland ML, Møller J, Junker P, Pødenphant J, Schlemmer A, Ellingsen T, Ahlquist P, Lindegaard H, Linauskas A, Dam MY, Hansen I, Horn HC, Ammitzbøll CG, Jørgensen A, Krintel SB, Raun J, Krogh NS, Johansen JS, Østergaard M; OPERA study group. Axelsen MB, et al. Among authors: schlemmer a. Ann Rheum Dis. 2015 May;74(5):867-75. doi: 10.1136/annrheumdis-2013-204537. Epub 2014 Jan 10. Ann Rheum Dis. 2015. PMID: 24412895 Clinical Trial.
Using a novel smartphone application for capturing of patient-reported outcome measures among patients with inflammatory arthritis:A randomized, crossover, agreement study.
Uhrenholt L, Christensen R, Dreyer L, Schlemmer A, Hauge EM, Krogh NS, Abildtoft MK, Taylor PC, Kristensen S. Uhrenholt L, et al. Among authors: schlemmer a. Scand J Rheumatol. 2022 Jan;51(1):25-33. doi: 10.1080/03009742.2021.1907925. Epub 2021 Jun 21. Scand J Rheumatol. 2022. PMID: 34151710 Clinical Trial.
Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial).
Uhrenholt L, Schlemmer A, Hauge EM, Christensen R, Dreyer L, Suarez-Almazor ME, Kristensen S. Uhrenholt L, et al. Among authors: schlemmer a. BMJ Open. 2019 Jul 9;9(7):e028517. doi: 10.1136/bmjopen-2018-028517. BMJ Open. 2019. PMID: 31292181 Free PMC article.
Prediction of treatment response to adalimumab: a double-blind placebo-controlled study of circulating microRNA in patients with early rheumatoid arthritis.
Krintel SB, Dehlendorff C, Hetland ML, Hørslev-Petersen K, Andersen KK, Junker P, Pødenphant J, Ellingsen T, Ahlquist P, Lindegaard HM, Linauskas A, Schlemmer A, Dam MY, Hansen I, Horn HC, Jørgensen A, Raun J, Ammitzbøll CG, Østergaard M, Stengaard-Pedersen K, Johansen JS. Krintel SB, et al. Among authors: schlemmer a. Pharmacogenomics J. 2016 Apr;16(2):141-6. doi: 10.1038/tpj.2015.30. Epub 2015 May 5. Pharmacogenomics J. 2016. PMID: 25939484 Clinical Trial.
75 results